187 related articles for article (PubMed ID: 28039923)
1. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
Ayoub HH; Abu-Raddad LJ
J Viral Hepat; 2017 Jun; 24(6):486-495. PubMed ID: 28039923
[TBL] [Abstract][Full Text] [Related]
2. Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections.
Ayoub HH; Abu-Raddad LJ
BMJ Open; 2019 May; 9(5):e026600. PubMed ID: 31133586
[TBL] [Abstract][Full Text] [Related]
3. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
[TBL] [Abstract][Full Text] [Related]
4. Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2021 Feb; 74(2):303-311. PubMed ID: 32931878
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
Durham DP; Skrip LA; Bruce RD; Vilarinho S; Elbasha EH; Galvani AP; Townsend JP
Clin Infect Dis; 2016 Feb; 62(3):298-304. PubMed ID: 26628566
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
7. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
[TBL] [Abstract][Full Text] [Related]
8. Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis.
Martin NK; Jansen K; An der Heiden M; Boesecke C; Boyd A; Schewe K; Baumgarten A; Lutz T; Christensen S; Thielen A; Mauss S; Rockstroh JK; Skaathun B; Ingiliz P
J Infect Dis; 2019 Oct; 220(10):1635-1644. PubMed ID: 31301142
[TBL] [Abstract][Full Text] [Related]
9. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
10. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
11. HCV in Egypt, prevention, treatment and key barriers to elimination.
El Kassas M; Elbaz T; Elsharkawy A; Omar H; Esmat G
Expert Rev Anti Infect Ther; 2018 Apr; 16(4):345-350. PubMed ID: 29506418
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatitis B and C in children.
El-Shabrawi M; Hassanin F
Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan.
Ayoub HH; Al Kanaani Z; Abu-Raddad LJ
J Viral Hepat; 2018 Jun; 25(6):670-679. PubMed ID: 29345847
[TBL] [Abstract][Full Text] [Related]
14. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
[TBL] [Abstract][Full Text] [Related]
16. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
[TBL] [Abstract][Full Text] [Related]
17. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study.
Walker JG; Kuchuloria T; Sergeenko D; Fraser H; Lim AG; Shadaker S; Hagan L; Gamkrelidze A; Kvaratskhelia V; Gvinjilia L; Aladashvili M; Asatiani A; Baliashvili D; Butsashvili M; Chikovani I; Khonelidze I; Kirtadze I; Kuniholm MH; Otiashvili D; Sharvadze L; Stvilia K; Tsertsvadze T; Zakalashvili M; Hickman M; Martin NK; Morgan J; Nasrullah M; Averhoff F; Vickerman P
Lancet Glob Health; 2020 Feb; 8(2):e244-e253. PubMed ID: 31864917
[TBL] [Abstract][Full Text] [Related]
18. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis.
Mohamoud YA; Mumtaz GR; Riome S; Miller D; Abu-Raddad LJ
BMC Infect Dis; 2013 Jun; 13():288. PubMed ID: 23799878
[TBL] [Abstract][Full Text] [Related]
19. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination.
Lim AG; Qureshi H; Mahmood H; Hamid S; Davies CF; Trickey A; Glass N; Saeed Q; Fraser H; Walker JG; Mukandavire C; Hickman M; Martin NK; May MT; Averhoff F; Vickerman P
Int J Epidemiol; 2018 Apr; 47(2):550-560. PubMed ID: 29309592
[TBL] [Abstract][Full Text] [Related]
20. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
